Year: 2001
Type: article
Abstract: Individuals with diabetes are at increased risk of developing microvascular complications (retinopathy, nephropathy, and neuropathy) and cardiovascular disease (CVD).The Diabetes Control and Complications Trial (DCCT) (1) and U.K. Prospective Diabetes Study (UKPDS) (2) showed that treatment programs resulting in improved glycemic control, as measured by HbA 1c , reduced the microvascular complications of diabetes.The effect of these treatment programs on reducing CVD was less clear.However, some epidemiological studies suggest that there may be a relationship between glycemic levels and CVD.In the management of diabetes, health care providers usually assess glycemic control with fasting plasma glucose (FPG) and premeal glucose measurements, as well as by measuring HbA 1c .Therapeutic goals for HbA 1c and preprandial glucose levels have been established based on the results of controlled clinical trials.Unfortunately, the majority of patients with diabetes fail to achieve their glycemic goals.Elevated postprandial glucose (PPG) concentrations may contribute to suboptimal glycemic control.Postprandial hyperglycemia is also one of the earliest abnormalities of glucose homeostasis associated with type 2 diabetes and is markedly exaggerated in diabetic patients with fasting hyperglycemia.Several therapies targeted toward lowering PPG excursions are now available and have been shown to improve glycemic control as measured by HbA 1c .However, many questions remain unanswered regarding the definition of PPG and, perhaps most importantly, whether postprandial hyperglycemia has a unique role in the pathogenesis of diabetic complications and should be a specific target of therapy.To address these issues and to provide guidance to health care providers, the American Diabetes Association (ADA) convened a consensus development conference on 24 -26 January 2001 in Atlanta, Georgia.A seven-member panel of experts in diabetes, endocrinology, and metabolism heard selected abstracts and presentations from invited speakers.The panel was then asked to develop a consensus position on the following questions:
Source: Diabetes Care
Author: Association, American Diabetes
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Eli Lilly and Company, Pfizer, Novo Nordisk
OpenAlex ID: W4213149640